A Comprehensive Review of Nanotechnological Innovations in Cancer: from Molecular Pathways to Clinical Applications

Résumé fourni par la source

This review offers an inclusive overview of current cancer treatment options. It examines emerging trends in molecular mechanisms, therapeutic challenges, and nanotechnological innovations that may significantly improve patient outcomes. Cancer is a complex disease characterized by unregulated cellular proliferation, invasion of adjacent tissues, and metastasis. It remains a leading cause of death worldwide, with increasing incidence attributed to factors such as an aging demographic, lifestyle habits, and environmental stimuli. This review examines various cancer types, their associated risk factors, and critical molecular pathways, with the PI3K/Akt/mTOR and Wnt/β-catenin pathways, that facilitate cancer progression. The intricate process of metastasis, the leading cause of cancer fatalities, is examined in depth. The discussion encompasses a comprehensive analysis of diagnostic methods and conventional treatment modalities, including surgical intervention, radiation therapy, chemotherapy, and targeted therapies, and addresses their limitations, including toxicity, drug resistance, and unintended side effects. The advent of nanoparticle-based platforms in cancer therapy has facilitated significant progress in targeted drug delivery, enhanced imaging for prompt diagnosis, and the advancement of treatments, such as photothermal and photodynamic therapies. Nanoparticles may provide a vital function in overcoming drug resistance, thereby improving treatment effectiveness. Furthermore, this review emphasizes cancer prevention strategies, which include lifestyle changes and vaccination efforts. The oncological treatment landscape is poised for transformation through advancements in precision medicine, gene therapy, and artificial intelligence. Incorporating nanotechnology into these emerging strategies holds substantial potential for developing more personalized and effective cancer therapies with reduced adverse effects.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.